Efficacy and Safety of Eslicarbazepine Acetate (BIA 2 093) as Therapy for Patients With Painful Diabetic Neuropathy: a Double-blind, Double-dummy, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial.
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Eslicarbazepine acetate (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- Sponsors Bial
- 09 Feb 2012 Additional location (Austria) added as reported by ClinicalTrials.gov.
- 23 Sep 2009 New trial record